PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743363
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743363
Systemic Lupus Erythematosus Market Growth, Size, Trends Analysis - By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Systemic Lupus Erythematosus Market Introduction and Overview
According to SPER market research, 'Global Systemic Lupus Erythematosus Market Size- By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Systemic Lupus Erythematosus Market is predicted to reach 5.81 billion by 2034 with a CAGR of 7.38%.
Systemic lupus Erythematosus (SLE) is the chronic autoimmune illness develops when the immune system mistakenly targets healthy tissues, leading to extensive inflammation and damage. Multiple organs, including the skin, joints, kidneys, heart, lungs, and brain, may be impacted. Fatigue, joint discomfort, skin rashes, and organ issues are among the frequent symptoms, although they might vary. While the precise origin is unknown, environmental, hormonal, and genetic variables all play a part. SLE frequently has a relapsing-remitting history and is more prevalent in women.
Restraints: Research has advanced, but our understanding of SLE remains incomplete, making it difficult to create novel medicines and enhance patient outcomes. Although there is currently no cure for SLE, not all patients respond well to the medications that are available. Access to care may be restricted for many patients with SLE because the cost of treatments can be unaffordable. Patients may be deterred from seeking therapy for SLE by the substantial adverse effects of some therapies. SLE can be challenging to diagnose, which could cause therapy delays and worse patient outcomes.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Drug Class, By Route of Administration, By Distribution Channel
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Novartis AG, GSK plc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, Lycera (Celgene), Bristol-Myers Squibb Company, ImmuPharma PLC, Merck KgaA, AstraZeneca, UCB S.A.
Global Systemic Lupus Erythematosus Market Segmentation:
By Drug Class: Based on the Drug Class, Global Systemic Lupus Erythematosus Market is segmented as; Biologics, TNF Inhibitors, NSAID's, Corticosteroids, Antimalarials, Immunosuppressants.
By Route of Administration: Based on the Route of Administration, Global Systemic Lupus Erythematosus Market is segmented as; Oral, Intravenous, Subcutaneous.
By Distribution Channel: Based on the Distribution Channel, Global Systemic Lupus Erythematosus Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.
Table of Contents
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER's internal database
2.1.4. Premium insight from KOL's
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER's Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Systemic Lupus Erythematosus Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Systemic Lupus Erythematosus Market
7. Global Systemic Lupus Erythematosus Market, By Drug Class 2021-2034 (USD Million)
7.1. Biologics
7.1.1. Saphnelo (Anifrolumab)
7.1.2. Benlysta (Belimumab)
7.1.3. Phase 3 Pipeline Products
7.2. TNF Inhibitors
7.3. NSAID's
7.4. Corticosteroids
7.5. Antimalarials
7.6. Immunosuppressants
8. Global Systemic Lupus Erythematosus Market, By Route of Administration 2021-2034 (USD Million)
8.1. Oral
8.2. Intravenous
8.3. Subcutaneous
9. Global Systemic Lupus Erythematosus Market, By Distribution Channel 2021-2034 (USD Million)
9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Online Pharmacy
10. Global Systemic Lupus Erythematosus Market, 2021-2034 (USD Million)
10.1. Global Systemic Lupus Erythematosus Market Size and Market Share
11. Global Systemic Lupus Erythematosus Market, By Region, 2021-2034 (USD Million)
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. AstraZeneca
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bristol-Myers Squibb Company
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. F. Hoffmann-La Roche Ltd
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. GSK plc.
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. ImmuPharma PLC
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Lycera (Celgene)
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Merck KgaA
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Novartis AG
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Pfizer Inc.
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Sanofi
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
